American investors love drama. So it is no surprise that Theranos is causing a stir. Just two months ago this blood diagnostics company — created a decade ago by Stanford dropout Elizabeth Holmes — was an investor darling valued at $9bn. Now, however, it faces allegations that its testing techniques were not as novel as claimed, and the company has become a lightning rod for wider investor concerns about the sky-high valuations now seen in Silicon Valley.
美国投资者喜欢戏剧性。因此，Theranos引起骚动并不令人意外。就在两个月前，这家血液诊断公司——10年前由斯坦福大学(Stanford)辍学生伊丽莎白•霍尔梅斯(Elizabeth Holmes)创建——还受到投资者的青睐，估值高达90亿美元。然而，如今该公司面临指控：其检测技术并不像该公司声称的那样新颖，同时该公司成了投资者对如今硅谷天价估值的更广泛担忧的典型对象。
您已阅读10%（646字），剩余90%（5709字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。